NAFLD or non alcoholic fatty liver disease is increasingly known as one of the main causes of chronic liver disease globally, growing rapidly linear with the increase of obesity, type 2 diabetes and metabolic syndromes. Liver fibrosis is key factor to predict the adverse reaction that caused by NAFLD. Liver biopsy is known for a long time to be the golden standard to diagnose liver fibrosis, but its high cost, and risky procedure is limiting its own benefit, therefore other diagnostic methods is developed. Transient elastography Fibroscan is the most accurate way to diagnose because the accuracy is similar with liver biopsy. Using ultrasound emiting probe to determine the stages of liver fibrosis. Simple diagnostic test using laboratory result is also developed, APRI score or AST/Platelet Ratio is a method that diagnose the existence and degree of liver fibrosis using result from simple blood tests. Significant positive correlations is found between Fibroscan and APRI result to diagnose the degrees of liver fibrosis on NAFLD patients from several study that conducted from different countries. Using them as a combination could avoid the needs to use liver biopsy to reduce cost and risk.

Transient Elastography

Fibroscan

NAFLD

APRI

Liver Fibrosis